secwatch.observer — SEC 8-K summary
======================================

Issuer:     COOPER COMPANIES, INC. (COO)
CIK:        0000711404
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0000711404-22-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CooperCompanies Q1 revenue up 16% to $787M; non-GAAP EPS $3.24
--------------------------------------------------------------

- Revenue $787.2M (+16% YoY); CooperVision +11% to $561.5M, CooperSurgical +30% to $225.7M.
- GAAP diluted EPS $1.91 (vs $42.31 prior year due to deferred tax benefit); non-GAAP diluted EPS $3.24 (+2%).
- Net debt $2,981.5M after Generate Life Sciences acquisition; adjusted leverage 2.71x.
- FY2022 guidance: revenue $3,261-$3,329M; non-GAAP EPS $13.70-$14.20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/711404/000071140422000010/0000711404-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/711404/000071140422000010/coo-20220303.htm
  HTML page:      https://secwatch.observer/filing/0000711404-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer